antineoplastons

Antineoplastons are a group of synthetic or naturally occurring peptides and amino acid derivatives originally isolated from human blood and urine. Developed in the 1970s by Dr. Stanislaw Burzynski, these compounds were hypothesized to have anticancer properties by selectively targeting cancer cells while sparing normal tissue. The main types include A10 (3-phenylacetylamino-2,6-piperidinedione), AS2-1 (a mixture of phenylacetic acid and phenylacetylglutamine), AS2-5 (phenylacetylglutamine), among others. Proposed mechanisms include regulation of gene expression, inhibition of abnormal cell division, induction of cancer cell differentiation, and possible immune system stimulation. Despite decades of research—primarily at the developer’s institute—there is insufficient evidence from independent or randomized controlled trials to support their efficacy for any disease. Antineoplaston therapy is not approved by the FDA or other major regulatory agencies[1][2][4][5][6].

Other names

antineoplaston therapyBurzynski antineoplastons